上海艾力斯医药科技股份有限公司2025年半年度报告摘要

Core Viewpoint - The company, Shanghai Ailis Pharmaceutical Technology Co., Ltd., has announced its 2025 semi-annual profit distribution plan, proposing a cash dividend of 4.00 RMB per 10 shares, totaling 180 million RMB, which represents 17.12% of the net profit for the first half of 2025 [2][16][15]. Company Overview - The company is listed under the stock code 688578 and is referred to as Ailis [3]. - The total share capital as of June 30, 2025, is 450 million shares [2][16]. Financial Data - The net profit attributable to shareholders for the first half of 2025 is 1,051,235,341.42 RMB [16]. - The undistributed profits of the parent company as of June 30, 2025, amount to 1,757,254,173.14 RMB [16]. Profit Distribution Plan - The proposed cash dividend is 4.00 RMB per 10 shares, with a total cash dividend of 180 million RMB (including tax) [2][16]. - The company will not issue bonus shares or increase capital reserves during this distribution [2][15]. Governance and Compliance - The board of directors and the supervisory board have confirmed the accuracy and completeness of the semi-annual report, ensuring no false statements or omissions [1][6]. - The supervisory board has reviewed and approved the semi-annual report and the profit distribution plan, affirming compliance with relevant laws and regulations [5][9]. Fund Management - The company has established a system for managing raised funds, ensuring they are stored in dedicated accounts and used according to regulations [22][23]. - As of June 30, 2025, the balance of the raised funds is 40,086,120.13 RMB, with a total of 1,436,697,370.69 RMB used [23][24]. Investment Projects - The company has adjusted its investment in research and development projects, increasing the total investment in the new drug development project to 106,615.87 million RMB [35][37]. - The company has also made changes to its fundraising project allocations, ensuring funds are used effectively for ongoing and new projects [39].